Skip navigation
Universidade de Brasília
Use este identificador para citar ou linkar para este item: http://repositorio.unb.br/handle/10482/55541
Arquivos associados a este item:
Não existem arquivos associados a este item.
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorSilva, Amanda C.pt_BR
dc.contributor.authorMachado, Michele R.pt_BR
dc.contributor.authorOliveira, Gerlon de Almeida Ribeiropt_BR
dc.contributor.authorCosta, Gessyca G.pt_BR
dc.contributor.authorOliveira, Gisele A. R.pt_BR
dc.contributor.authorLião, Luciano M.pt_BR
dc.contributor.authorGil, Eric S.pt_BR
dc.contributor.authorMenegatti, Ricardopt_BR
dc.contributor.authorSilva, Gloria N. S.pt_BR
dc.date.accessioned2026-07-30T13:49:24Z-
dc.date.available2026-07-30T13:49:24Z-
dc.date.issued2025-10pt_BR
dc.identifier.citationSILVA, Amanda C. et al. Toxicity assessment of a derivative designed by using the privileged structure Dihydropyridine: LQFM310, a Nifedipine analog. Journal of Applied Toxicology, [S. l.], v. 45, n. 10, 2025. Disponível em: https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/jat.4829. Acesso em: 30 jul. 2026.pt_BR
dc.identifier.urihttps://doi.org/10.1002/jat.4829pt_BR
dc.identifier.urihttp://repositorio.unb.br/handle/10482/55541-
dc.publisherWileypt_BR
dc.rightsAcesso Restritopt_BR
dc.titleToxicity assessment of a derivative designed by using the privileged structure dihydropyridine : LQFM310, a nifedipine analogpt_BR
dc.typeArtigopt_BR
dc.subject.keywordFitoterapia-
dc.subject.keywordParacetamol-
dc.subject.keywordAtividade hepatoprotetora-
dc.identifier.doihttps://doi.org/10.1002/jat.4829pt_BR
dc.relation.publisherversionhttps://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/jat.4829-
dc.description.abstract1The privileged structures, such as dihydropyridine, are present in bioactive compounds exhibiting biological activities by interacting with multiple pharmacological targets. The dihydropyridine‐containing compounds are usually related to the calcium channel–blocking abilities in the treatment of cardiovascular diseases, such as nifedipine. Other pharmaceutical applications have been described for these compounds, being a starting point for the obtaining of new drug candidates. The privileged structures are usually related to nontoxic effects; however, other chemical groups of dihydropyridine‐containing compounds may result in impairment of the safety profile, such as nifedipine, described as teratogenic and embryotoxic in vivo. Here, we designed LQFM310 through the molecular hybridization strategy by incorporating the dimethyl 2,6‐dimethyl‐1,4‐dihydropyridine‐3,5‐dicarboxylate scaffold from nifedipine and butyl hydroxytoluene (BHT). As the phenolic hydroxyl from BHT is capable of conferring antioxidant activity, the electrochemical analysis was performed. In addition, the toxicological profile of LQFM310 was investigated by using the embryo‐larval stage of zebrafish ( Danio rerio ) and compared to nifedipine. As a result, LQFM310 demonstrated the antioxidant potential and did not induce significant lethal or sublethal effects in the toxicological assay. However, nifedipine induced 100% mortality in embryos and larvae from 25 μM for 96 h post fertilization (hpf) and sublethal effects at 10 μM. Therefore, LQFM310 demonstrated a safer profile than nifedipine in the zebrafish‐based toxicity model, identifying that the nitroaromatic scaffold may be responsible for the toxicity effect of nifedipine. Considering the presence of privileged structures as dihydropyridine, LQFM310 is a promising compound for investigation in pharmacology assays of several diseases.pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-1547-5354pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-7936-5429pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-9985-2980pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0001-9161-0127pt_BR
dc.identifier.orcidhttps://orcid.org/0000-0002-6584-201Xpt_BR
dc.contributor.affiliationLaboratory of Medicinal Pharmaceutical Chemistry (LQFM), School of Pharmacy Federal University of Goiás Goiânia Goiás Brazilpt_BR
dc.contributor.affiliationEnvironmental Toxicology Research Laboratory (EnvTox), School of Pharmacy Federal University of Goiás Goiânia Goiás Brazilpt_BR
dc.contributor.affiliationEnvironmental Toxicology Research Laboratory (EnvTox), School of Pharmacy Federal University of Goiás Goiânia Goiás Brazilpt_BR
dc.contributor.affiliationDepartment of Pharmacy Faculty of Health Sciences University of Brasília Brasília Brazilpt_BR
dc.contributor.affiliationEnvironmental Toxicology Research Laboratory (EnvTox), School of Pharmacy Federal University of Goiás Goiânia Goiás Brazilpt_BR
dc.contributor.affiliationEnvironmental Toxicology Research Laboratory (EnvTox), School of Pharmacy Federal University of Goiás Goiânia Goiás Brazilpt_BR
dc.contributor.affiliationNuclear Magnetic Resonance Laboratory (LabRMN), Institute of Chemistry Federal University of Goiás, Campus Samambaia Goiânia Goiás Brazilpt_BR
dc.contributor.affiliationSchool of Pharmacy Federal University of Goiás Goiânia Goiás Brazilpt_BR
dc.contributor.affiliationLaboratory of Medicinal Pharmaceutical Chemistry (LQFM), School of Pharmacy Federal University of Goiás Goiânia Goiás Brazilpt_BR
dc.contributor.affiliationLaboratory of Medicinal Pharmaceutical Chemistry (LQFM), School of Pharmacy Federal University of Goiás Goiânia Goiás Brazilpt_BR
dc.contributor.affiliationSchool of Pharmacy Federal University of Bahia, Campus Ondina Salvador Bahia Brazilpt_BR
dc.description.unidadeFaculdade de Ciências da Saúde (FS)pt_BR
dc.description.unidadeDepartamento de Farmácia (FS FAR)pt_BR
Aparece nas coleções:Artigos publicados em periódicos e afins

Mostrar registro simples do item Visualizar estatísticas



Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.